Navigation Links
Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases

ucted by Dr Arthur Frankel and his team at the Cancer Research Institute of Scott and White Memorial Hospital in collaboration with scientists at Protox and Johns Hopkins University. Key findings include: human prostate cancer cells are significantly more sensitive to PRX302 in the presence of active PSA; PRX302 was totally resistant to thrombin, matrix metalloprotease 7 (MMP-7), human kallikrein 1 (hk1) and human kallikrein 2 (hk2) activation; and among the normal cells tested, the PSA-producing prostate epithelial cells were the only normal cells that were highly sensitive to PRX302.

Both publications demonstrated that the PSA-activated strategy for PRX302 has a number of inherent advantages as a therapeutic strategy for locally recurrent prostate cancer and BPH.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain st
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/1/2015)... , July 1, 2015   Cochlear Limited ... hearing solutions, announced today the US Food and ... Profile™ Implant with Slim Straight Electrode (CI522). Built ... in close collaboration with the world,s leading surgeons, ... platform designed to provide the most discreet appearance ...
(Date:7/1/2015)... 24, 2015 ... the addition of the "2015 New ... Markets: Business Challenges, Emerging Technologies, Competitive Landscape" ... 2015 New Frontiers in European Clinical Chemistry ... Competitive Landscape is a new five-country strategic ...
(Date:7/1/2015)... July 1, 2015  goBalto, Inc., the leading ... today unprecedented growth in serving pharmaceutical, biotech and ... to speed clinical trials and restrain costs, but ... methods have stalled these efforts," said Sujay ... clinical trials has encouraged Industry leaders, to embrace ...
Breaking Medicine Technology:Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 32015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2
... 2011 Aerocrine, Inc., an innovative medical technology company ... has selected R&J Public Relations, LLC of Bridgewater, N.J., ... conduct strategic public relations for the Aerocrine brand; most ... and only hand-held device available to measure exhaled nitric ...
... Reportlinker.com announces that a new market research report ... Telemedicine: Opportunities for Medical and Electronic Providers ... global telemedicine market is expected to grow from $9.8 ... a compound annual growth rate (CAGR) of 18.6% over ...
Cached Medicine Technology:R&J Public Relations Named Agency of Record for Aerocrine, Inc. 2Reportlinker Adds Telemedicine: Opportunities for Medical and Electronic Providers 2Reportlinker Adds Telemedicine: Opportunities for Medical and Electronic Providers 3Reportlinker Adds Telemedicine: Opportunities for Medical and Electronic Providers 4Reportlinker Adds Telemedicine: Opportunities for Medical and Electronic Providers 5
(Date:7/2/2015)... ... ... DUI arrests and fatalities spike on the 4th of July. In fact, because of drunk ... comes to being on the road. According to attorney David J. Maloney , the ... highway deaths between 2007 and 2011 were caused by drunk driving over the 4th of ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... It’s no secret that what we consume can have an effect on ... people can easily feel dehydrated or perhaps even undernourished if not eating enough of the right ... can be an easy time of year to overdo it on the food front as well, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... To Resource" for Semiconductor Timing announced the release and publication of their newest ... a Quarterly based publication and Newsletter. , Designed in support of coverage ...
(Date:7/1/2015)... Angeles, CA (PRWEB) , ... July 01, 2015 , ... ... the great outdoors. Yet, in many Middle-Eastern countries like Saudi Arabia and Dubai, the ... to relax in more temperate climates. Celebrity dentist Dr. Sam Saleh of ORA Dentistry ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. ... West Virginia on June 26th, the Court rejected the Plaintiff’s assertion that ...
Breaking Medicine News(10 mins):Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3
... Raises Caution on Using Signal Transduction Inhibitors,in Children -, ... eliminated brain tumors from mice in a dramatic 2004 ... damage in younger mice. The,researcher who conducted both studies ... drugs to treat children,s cancers, at,least until there is ...
... All Stages Steps Away From Home, ... ... of,South Carolina (MUSC) Foundation for Research and Development announced a,promising new ... cancer have shown to be accurate for only 40 percent of,diagnoses. ...
... DC (March 5, 2008): Addressing questions about climate change, ... in a recent survey, Student Pugwash USA launched From ... to the 2008 elections. , From Electrons to ... voters on science, technology, and health issues and provide ...
... CITY, March 10 ZARS Pharma, Inc. ... Galderma Pharma S.A. the,exclusive promotion and distribution ... and Canada for Pliaglis(TM) (lidocaine and tetracaine) ... and safe local,anesthesia in patients undergoing potentially ...
... Scientists have established a mouse model for human malignant ... development and progression along with new directions for design ... in the March issue of Cancer Cell, may eventually ... this devastating disease. , MM is an aggressive ...
... that can occur in babies with congenital heart disease is the ... results in too much blood in the lungs, more blood vessels ... vessel growth is abruptly halted. , You get this burst in ... think the system gets shut down and the lungs dont get ...
Cached Medicine News:Health News:Potential Brain Cancer Drug for Children May Damage Bones 2Health News:Potential Brain Cancer Drug for Children May Damage Bones 3Health News:Cell Receptor on Track for Painless Bladder Cancer Test 2Health News:Student Pugwash USA launches science policy election guide for young voters 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3Health News:Mouse model for mesothelioma reproduces human disease 2Health News:Lung damage in babies with congenital heart disease under study 2Health News:Lung damage in babies with congenital heart disease under study 3
... PDA Closure Device has been developed for ... Arteriosus. Introduced through standard venous sheaths (10-14F) ... method for the percutaneous closure of persistent ... within the ductus.,An integral locking delivery and ...
Stainless steel plain Steinman Pins available in point types A through F....
Full pin skeletal traction pins with cove point....
Calibrated Guide Pins have a 12.7 mm calibration and are available in plain, with a threaded tip, or with a trocar point....
Medicine Products: